flurbiprofen has been researched along with dapsone in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Hauer, MJ; Hutzler, JM; Tracy, TS | 1 |
| Branch, RA; Frye, RF; Huang, SM; Hutzler, JM; Korzekwa, KR; Tracy, TS | 1 |
| Hummel, MA; Hutzler, JM; Kolwankar, D; Tracy, TS | 1 |
| Carlson, TJ; Hutzler, JM; Tracy, TS; Wahlstrom, JL; Wienkers, LC | 1 |
| Dickmann, LJ; Haining, RL; Hummel, MA; Rettie, AE; Tracy, TS | 1 |
| Aguilar, JS; Gannett, PM; Hummel, MA; Tracy, TS | 1 |
| Branch, RA; Frye, RF; Romkes, M; Tracy, TS; Zgheib, NK | 1 |
| Ayscue, R; Gannett, PM; Locuson, CW; Tracy, TS | 1 |
| Bostick, CD; Flora, DR; Gannett, PM; Lederman, D; Tracy, TS | 1 |
2 review(s) available for flurbiprofen and dapsone
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for flurbiprofen and dapsone
| Article | Year |
|---|---|
Validation of incorporating flurbiprofen into the Pittsburgh cocktail.
Topics: Administration, Oral; Adolescent; Adult; Aged; Caffeine; Chlorzoxazone; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Therapy, Combination; Female; Flurbiprofen; Genotype; Humans; Isoenzymes; Male; Mephenytoin; Middle Aged | 2006 |
14 other study(ies) available for flurbiprofen and dapsone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Activation; Flurbiprofen; Hydroxylation; Models, Chemical; Naproxen; Piroxicam; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Substrate Specificity | 2001 |
Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Dapsone; Enzyme Activation; Enzyme Activators; Flurbiprofen; Indicators and Reagents; Kinetics; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Dealkylation; Flurbiprofen; Hydroxylation; Kinetics; Naproxen; Structure-Activity Relationship; Substrate Specificity | 2002 |
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Flurbiprofen; Humans; Hydroxylation; Inactivation, Metabolic; Kinetics; Mechanics; Models, Biological; NADP; Oxygen | 2003 |
Differential activation of CYP2C9 variants by dapsone.
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Enzyme Activation; Flurbiprofen; Humans; Hydroxylation; Kinetics; Naproxen; Substrate Specificity | 2004 |
Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Dapsone; Enzyme Activation; Flurbiprofen; Heme; Humans; Hydroxylation; Iron; Magnetic Resonance Spectroscopy; Models, Molecular; Protein Binding; Protein Conformation; Substrate Specificity | 2004 |
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Dapsone; Databases, Factual; Enzyme Activators; Enzyme Inhibitors; Flurbiprofen; Humans; Models, Molecular; Molecular Structure; NADPH-Ferrihemoprotein Reductase; Quantitative Structure-Activity Relationship; Rats | 2007 |
Nanoscale electron transport measurements of immobilized cytochrome P450 proteins.
Topics: Aniline Compounds; Catalytic Domain; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Dapsone; Electric Conductivity; Electron Transport; Electrons; Flurbiprofen; Gold; Humans; Immobilized Proteins; Metal Nanoparticles; Microscopy, Electron, Scanning; Protein Binding; Protein Conformation; Protein Engineering; Silicon; Sulfaphenazole | 2015 |